...
tgtx-img

TG Therapeutics Inc, Common Stock

TGTX

NAQ

$32.26

+$0.06

(0.19%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$5.01B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
959.42K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.19
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$12.84 L
$36.84 H
$32.26

About TG Therapeutics Inc, Common Stock

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameTGTXSectorS&P500
1-Week Return-6.22%-0.94%-2.6%
1-Month Return-6.79%-5.08%-1.08%
3-Month Return38.75%-10.62%3.45%
6-Month Return75.23%-6.18%8.57%
1-Year Return89.88%1.98%24.3%
3-Year Return66.37%-0.93%25.58%
5-Year Return193.01%33.84%84.07%
10-Year Return105.48%102.52%185.12%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue152.00K152.00K6.69M2.79M233.66M[{"date":"2019-12-31","value":0.07,"profit":true},{"date":"2020-12-31","value":0.07,"profit":true},{"date":"2021-12-31","value":2.86,"profit":true},{"date":"2022-12-31","value":1.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue282.00K374.00K790.00K265.00K14.55M[{"date":"2019-12-31","value":1.94,"profit":true},{"date":"2020-12-31","value":2.57,"profit":true},{"date":"2021-12-31","value":5.43,"profit":true},{"date":"2022-12-31","value":1.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(130.00K)(222.00K)5.90M2.52M219.11M[{"date":"2019-12-31","value":-0.06,"profit":false},{"date":"2020-12-31","value":-0.1,"profit":false},{"date":"2021-12-31","value":2.69,"profit":true},{"date":"2022-12-31","value":1.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(85.53%)(146.05%)88.19%90.48%93.77%[{"date":"2019-12-31","value":-91.21,"profit":false},{"date":"2020-12-31","value":-155.75,"profit":false},{"date":"2021-12-31","value":94.05,"profit":true},{"date":"2022-12-31","value":96.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses169.21M273.75M350.67M195.36M198.47M[{"date":"2019-12-31","value":48.25,"profit":true},{"date":"2020-12-31","value":78.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":55.71,"profit":true},{"date":"2023-12-31","value":56.6,"profit":true}]
Operating Income(169.06M)(273.59M)(344.77M)(192.84M)20.63M[{"date":"2019-12-31","value":-819.34,"profit":false},{"date":"2020-12-31","value":-1326,"profit":false},{"date":"2021-12-31","value":-1670.96,"profit":false},{"date":"2022-12-31","value":-934.61,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(9.10M)(12.12M)(8.97M)(15.69M)(20.19M)[{"date":"2019-12-31","value":-910300000,"profit":false},{"date":"2020-12-31","value":-1211600000,"profit":false},{"date":"2021-12-31","value":-896900000,"profit":false},{"date":"2022-12-31","value":-1568700000,"profit":false},{"date":"2023-12-31","value":-2018600000,"profit":false}]
Pre-Tax Income(172.87M)(279.38M)(348.10M)(198.34M)13.06M[{"date":"2019-12-31","value":-1323.47,"profit":false},{"date":"2020-12-31","value":-2138.88,"profit":false},{"date":"2021-12-31","value":-2664.99,"profit":false},{"date":"2022-12-31","value":-1518.41,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income Taxes6.48M6.50M7.45M5.50M390.00K[{"date":"2019-12-31","value":86.91,"profit":true},{"date":"2020-12-31","value":87.2,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":73.76,"profit":true},{"date":"2023-12-31","value":5.23,"profit":true}]
Income After Taxes(179.35M)(285.88M)(355.55M)(203.83M)12.67M[{"date":"2019-12-31","value":-1415.3,"profit":false},{"date":"2020-12-31","value":-2255.98,"profit":false},{"date":"2021-12-31","value":-2805.81,"profit":false},{"date":"2022-12-31","value":-1608.51,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income From Continuous Operations(172.87M)(279.38M)(348.10M)(182.65M)12.67M[{"date":"2019-12-31","value":-1364.2,"profit":false},{"date":"2020-12-31","value":-2204.71,"profit":false},{"date":"2021-12-31","value":-2747.01,"profit":false},{"date":"2022-12-31","value":-1441.35,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(179.35M)(285.88M)(355.55M)(203.83M)12.67M[{"date":"2019-12-31","value":-1415.3,"profit":false},{"date":"2020-12-31","value":-2255.98,"profit":false},{"date":"2021-12-31","value":-2805.81,"profit":false},{"date":"2022-12-31","value":-1608.51,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
EPS (Diluted)(1.98)(2.27)(2.63)(1.46)0.01[{"date":"2019-12-31","value":-19800,"profit":false},{"date":"2020-12-31","value":-22700,"profit":false},{"date":"2021-12-31","value":-26300,"profit":false},{"date":"2022-12-31","value":-14600,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

TGTX
Cash Ratio 2.73
Current Ratio 4.59
Quick Ratio 3.91

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TGTX
ROA (LTM) -0.07%
ROE (LTM) -8.05%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TGTX
Debt Ratio Lower is generally better. Negative is bad. 0.67
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.33

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TGTX
Trailing PE NM
Forward PE 23.36
P/S (TTM) 18.93
P/B 26.10
Price/FCF NM
EV/R 18.61
EV/Ebitda 846.50
PEG NM

FAQs

What is TG Therapeutics Inc share price today?

TG Therapeutics Inc (TGTX) share price today is $32.26

Can Indians buy TG Therapeutics Inc shares?

Yes, Indians can buy shares of TG Therapeutics Inc (TGTX) on Vested. To buy TG Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TGTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of TG Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of TG Therapeutics Inc (TGTX) via the Vested app. You can start investing in TG Therapeutics Inc (TGTX) with a minimum investment of $1.

How to invest in TG Therapeutics Inc shares from India?

You can invest in shares of TG Therapeutics Inc (TGTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in TGTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in TG Therapeutics Inc shares
What is TG Therapeutics Inc 52-week high and low stock price?

The 52-week high price of TG Therapeutics Inc (TGTX) is $36.84. The 52-week low price of TG Therapeutics Inc (TGTX) is $12.84.

What is TG Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of TG Therapeutics Inc (TGTX) is

What is TG Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of TG Therapeutics Inc (TGTX) is 26.10

What is TG Therapeutics Inc dividend yield?

The dividend yield of TG Therapeutics Inc (TGTX) is 0.00%

What is the Market Cap of TG Therapeutics Inc?

The market capitalization of TG Therapeutics Inc (TGTX) is $5.01B

What is TG Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of TG Therapeutics Inc is TGTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top